论文部分内容阅读
目的观察用脑脉泰胶囊治疗脑梗死的临床疗效。方法在为我院收治的80例脑梗死患者进行治疗的过程中,随机将其分为治疗组和对照组,每组40例患者。为两组患者进行抗血小板、扩张血管、改善微循环及营养神经细胞等常规治疗,并为治疗组患者使用脑脉泰胶囊进行治疗。结果治疗组患者在治疗4周后,有11例患者基本治愈,有15例患者显效,有13例患者有效,有1例患者无效,显效率为65.0%。对照组患者在治疗4周后,有5例患者基本治愈,有10例患者显效,有20例患者有效,有5例患者无效,显效率为37.5%。治疗组患者的疗效明显优于对照组患者。结论在为脑梗死患者进行常规治疗基础上加用脑脉泰胶囊可大大提高疗效。此法值得在临床中推广应用。
Objective To observe the clinical effect of Naomaitai capsule on cerebral infarction. Methods 80 patients admitted to our hospital for treatment of patients with cerebral infarction, were randomly divided into treatment group and control group, 40 patients in each group. For two groups of patients anti-platelet, dilate blood vessels, improve microcirculation and nutrition nerve cells and other conventional treatment, and for the treatment group of patients using cerebral vein capsule for treatment. Results In the treatment group, 11 patients were basically cured after 4 weeks of treatment, 15 patients were markedly effective, 13 patients were effective, 1 patient was ineffective, and the effective rate was 65.0%. In the control group, 5 patients were basically cured after 4 weeks of treatment, 10 patients were markedly effective, 20 patients were effective, 5 patients were ineffective, and the effective rate was 37.5%. The efficacy of the treatment group was significantly better than that of the control group. Conclusion In patients with cerebral infarction on the basis of conventional treatment with Naomaitai capsule can greatly enhance the efficacy. This method is worth promoting in clinical application.